1. Home
  2. VHI vs FULC Comparison

VHI vs FULC Comparison

Compare VHI & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

VHI

Valhi Inc.

HOLD

Current Price

$14.09

Market Cap

405.3M

Sector

Industrials

ML Signal

HOLD

Logo Fulcrum Therapeutics Inc.

FULC

Fulcrum Therapeutics Inc.

HOLD

Current Price

$3.64

Market Cap

467.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VHI
FULC
Founded
1932
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
405.3M
467.8M
IPO Year
1994
2019

Fundamental Metrics

Financial Performance
Metric
VHI
FULC
Price
$14.09
$3.64
Analyst Decision
Sell
Buy
Analyst Count
1
8
Target Price
$12.00
$16.38
AVG Volume (30 Days)
11.6K
4.2M
Earning Date
05-07-2026
04-27-2026
Dividend Yield
2.19%
N/A
EPS Growth
N/A
N/A
EPS
0.07
N/A
Revenue
$2,077,000,000.00
N/A
Revenue This Year
$33.32
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$196.07
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.44
$2.83
52 Week High
$20.00
$15.74

Technical Indicators

Market Signals
Indicator
VHI
FULC
Relative Strength Index (RSI) 42.21 32.75
Support Level $12.74 $2.83
Resistance Level $14.54 $8.18
Average True Range (ATR) 0.54 0.27
MACD -0.02 0.02
Stochastic Oscillator 0.00 20.76

Price Performance

Historical Comparison
VHI
FULC

About VHI Valhi Inc.

Valhi Inc is a holding company that provides chemicals, security products, waste management systems, and real estate development and management services through its subsidiaries. It operates its business in three segments, which are Chemicals, Component Products, and Real Estate Management and Development. The company derives maximum revenue from the Chemicals segment, which produces and markets value-added titanium dioxide pigments (TiO2). TiO2 is used to impart whiteness, brightness, opacity, and durability to various products, including paints, plastics, paper, fibers, and ceramics. Geographically, the company generates maximum revenue from the United States and also has a presence in Germany, Canada, Norway, and Belgium.

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Share on Social Networks: